Business Context and Reporting Period
This Form 8-K Current Report is filed by Capricor Therapeutics, Inc. for the reporting period ending June 30, 2017. The filing addresses the termination of a material definitive agreement between Capricor, Inc. (a wholly-owned subsidiary) and Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson), originally entered into on December 27, 2013.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Termination of Collaboration: Janssen Biotech, Inc. informed Capricor on June 30, 2017, that it will not exercise its exclusive option right to exploit CAP-1002 and certain allogeneic cardiospheres in the field of cardiology.
- Retention of Rights: As a result of the termination, Capricor retains full rights to CAP-1002 in all indications.
- Licensing Arrangements: Capricor secured an irrevocable, fully paid-up non-exclusive license under Janssen-controlled patents utilized in the production of clinical trial materials. Additionally, Capricor received a non-exclusive perpetual license to publish, disclose, and use Janssen information related to the CMC development plan.
Outlook, Risks, and Management Commentary
On July 6, 2017, the Company issued a press release (Exhibit 99.1) announcing the termination and the retention of full rights to CAP-1002. The filing notes that the information provided is for Regulation FD disclosure purposes and is not deemed filed for purposes of Section 18 of the Exchange Act. No specific financial guidance, risk factors, or contingencies regarding future performance are detailed in this specific document.
Investor Verification Checklist
- Verify the full text of the July 6, 2017 press release (Exhibit 99.1) for detailed strategic implications.
- Confirm the scope of the "fully paid-up non-exclusive license" regarding Janssen patents to ensure no future royalty obligations exist.
- Review subsequent filings (e.g., 10-Q or 10-K) for any financial impact or restructuring costs associated with the termination of the CMC Development Plan.
- Assess the Company's updated commercialization strategy for CAP-1002 now that it holds exclusive rights in all indications.